By Emma Spary and Justin Rivest
The project “Selling the Exotic in Paris and Versailles, 1670-1730”, running in the Faculty of History at the University of Cambridge, and funded by Leverhulme Research Grant 2014-289, held its planned workshop in April this year. Its theme, “Consumers of the Exotic: European commerce and the consumption of exotic materia medica, 1670-1730”, brought together a group of international scholars working on these questions in a broad variety of European contexts.
Our goal at the workshop was to produce a comparative picture of the ways in which exotic plant materials were processed, bought and consumed in Europe. Why did European consumers buy—and more significantly ingest—exotic plant materials? What did exoticism mean to them? While recent work has focused on colonial bioprospecting and the appropriation of indigenous knowledge, our aim was to investigate demand within Europe itself, exploring divergences and similarities across contexts. The choice of a restricted timespan—the decades around 1700—provided a baseline for comparison of drug production, sales and consumption in different cultures. Alexandra Cook (University of Hong Kong) kicked off the programme with a study of a proprietary drug, Garcin’s “Maduran pills”, sold around Europe in the early eighteenth century by an entrepreneur whose Protestant faith led to a complex intellectual and commercial itinerary. Cook argued that exotic ingredients were not necessarily a selling point for eighteenth-century patients. Harun Küçük (University of Pennsylvania) provoked us to think about the complexity of defining the exotic, and the importance of a multi-perspectival view of the history of drugs: Ottoman healers associated New World exotica like cinchona bark and ipecacuanha root with French medicine, since these substances often reached them via French commercial and intellectual networks. Continuing the global theme, Samir Boumediene explored the place of drugs in the missionary activities of the Society of Jesus. The decades around 1700 represented a decline in the relative importance of Jesuits in the global drug trade, as new players came to disrupt their initial privileged position.
Šebestián Kroupa (University of Cambridge) offered a counterpoint to the workshop’s focus on European consumption by exploring the supply of European drugs to transplanted European populations—Manila in the Philippines. European drugs were in fact imported in large volumes to this “exotic” locale; little attention was paid to the pursuit of plant substances that might be commodified in the metropole, an exception being the Saint Ignatius bean. Victoria Pickering explored the diverse trajectories, contacts, and exchanges that were necessary to assemble the massive collection of exotic plant substances of Sir Hans Sloane.
Moving to early modern Russia, Clare Griffin suggested that its unique geographical connections—in the form of a land route between Europe and the Far East—led commentators to represent distant substances and peoples as subject to incorporation into the Empire, rather than “exotic” in the sense of “foreign”, as the case of rhubarb showed. Paula De Vos concluded the first day with an account of Palacios’ prominent 1706 pharmacopoeia. Early modern Western pharmacy was indebted, for its materia medica, to the Indo-Mediterranean world rather than the continent of Europe. The slow appropriation of new drugs spread outwards from this Indo-Mediterranean core to the Silk Roads, the Indian Ocean, and eventually the Atlantic world.
On day 2, Laia Portet explored the architecture of exoticism in printed French materia medica. Where familiar European plants tended to be classified alphabetically, unfamiliar exotics were classified by parts (roots, barks, leaves) since this was the form in which they entered the European marketplace. Emma Spary used a case history of an exotic aromatic, cinnamon, to point up the disjuncture between textual, material and empirical knowledge of drugs, a conundrum for medical experts, market regulators and individual consumers. Hjalmar Fors provocatively suggested that for early modern Europeans, “the exotic” primarily evoked traded material goods, including spices and drugs, rather than foreign peoples or distant geographies. Lack of knowledge about the places of origin of drugs was critical to a substance remaining “exotic” in European eyes.
Justin Rivest spoke of the encounter between political power, the emerging state and the large-scale administration of drugs in France, looking at how personal trialling of drugs by successive ministers of war led to a centrally administered programme of dispensing exotic drugs like tobacco, quinquina and ipecacuanha to French troops. In a very different take on the end-user, Wouter Klein introduced us to the uses of print culture as a research tool for relating newspaper advertising and ships’ cargoes of drugs in the Dutch republic after 1700.
Several common themes emerged from the papers. It seemed that “colonial bioprospecting” had its limits as a way of understanding European engagement with non-European materia medica. Most substances discussed did not reach Europe thanks to state intervention, but rather were trafficked by a heterogenous set of actors: missionaries, trading company officials, entrepreneurial merchants and court physicians. Many papers also showed that “exoticism” was not necessarily inherently desirable. A drug’s value was established through consensus-building over time. Furthermore, “exoticism” was a relative, context-specific category, subject to change, not solely a feature of geographic origin, or of a core-periphery relation between European metropoles and their colonies. The papers demonstrated that exoticism was also, perhaps largely, a product of degrees of familiarity and unfamiliarity, which varied widely across different European contexts. In sum, rather than being inherently valuable objects of appropriation, exotic drugs were socially constructed goods.